Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - does it depend on the reason for withdrawal from the previous treatment?

Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Linde, Louise; Jacobsson, Lennart; Nissen, Michael J; Kristianslund, Eirik Klami; Santos, Maria José; Nordström, Dan; Rotar, Ziga; Gudbjornsson, Bjorn; Onen, Fatos; Codreanu, Catalin; Lindström, Ulf; Möller, Burkhard; Kvien, Tore K; Barcelos, Anabela; Eklund, Kari K; Tom, Matija; Love, Thorvardur Jon; Can, Gercek; ... (2024). Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - does it depend on the reason for withdrawal from the previous treatment? (In Press). Joint bone spine, 91(4), p. 105729. Elsevier 10.1016/j.jbspin.2024.105729

Preview

Text 1-s2.0-S1297319X2400040X-main.pdf - Accepted Version Available under License Creative Commons: Attribution (CC-BY). Download (862kB) | Preview

OBJECTIVE

To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment.

METHODS

Prospectively collected routine care data from 12 European registries were pooled. Retention rates (Kaplan-Meier estimation) and crude/LUNDEX-adjusted rates of Disease Activity Score 28 and Disease Activity index for PSoriatic Arthritis (DAS28 and DAPSA28) remission were calculated and compared with adjusted cox regression analyses and Chi-squared test, respectively).

RESULTS

We included 5233 (2nd TNFi) and 1906 (3rd TNFi) patients. Twelve-month retention rates for the 2nd and 3rd TNFi were 68% (95%CI: 67-70%) and 66% (64-68%), respectively. Patients who stopped the previous TNFi due to AE/LOE had 12-month retention rates of 66%/65% (2nd TNFi), and 65%/63% (3rd TNFi), respectively. Patients who stopped the previous TNFi due to LOE after less vs more than 24 weeks had 12-month retention rates of 54%/69% (2nd TNFi), and 58%/65% (3rd TNFi).Six-month crude/LUNDEX-adjusted DAS28 remission rates were 48%/35% and 38%/27%, and DAPSA28 remission rates were 19%/14% and 14%/10%, for the 2nd and 3rd TNFi.

CONCLUSION

Two-thirds of patients remained on TNFi at 12 months for both the 2nd and 3rd TNFi, while one-third and one-quarter of patients were in DAS28 remission after 6 months on the 2nd and 3rd TNFi. While drug effectiveness was similar in patients who stopped the previous TNFi due to AE compared to overall LOE, drug effectiveness was better in patients who had stopped the previous TNF due to secondary LOE compared to primary LOE.

Interest & Impact

Downloads

1 since deposited on 08 Apr 2024
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item